Blood test may predict chemo nerve damage risk

NCT ID NCT06430814

Recruiting now Knowledge-focused Sponsor: University of Southern Denmark Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 29 times

Summary

This study aims to find out if a simple blood test can identify breast cancer patients at higher risk of nerve damage from the chemotherapy drug paclitaxel. Researchers will measure a protein called NFL in the blood after the first treatment cycle to see if it predicts who will need to stop treatment early due to nerve pain or numbness. The study involves 188 adults with breast cancer who have not had paclitaxel before.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Odense University Hospital
RECRUITING

Odense, 5000, Denmark

Contact Phone: •••-•••-•••• Email: •••••@•••••
University Hospital of Southern Denmark, Sønderborg
RECRUITING

Sønderborg, 6400, Denmark

Contact Phone: •••-•••-•••• Email: •••••@•••••
University Hospital of Southern Denmark, Vejle
RECRUITING

Vejle, 7100, Denmark

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY